85 results on '"Kessels, L."'
Search Results
2. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
- Author
-
Charehbili, A., Hamdy, N.A.T., Smit, V.T.H.B.M., Kessels, L., van Bochove, A., van Laarhoven, H.W., Putter, H., Meershoek-Klein Kranenbarg, E., van Leeuwen-Stok, A.E., van der Hoeven, J.J.M., van de Velde, C.J.H., Nortier, J.W.R., and Kroep, J.R.
- Published
- 2016
- Full Text
- View/download PDF
3. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
- Author
-
Charehbili, A., van de Ven, S., Smit, V.T.H.B.M., Meershoek-Klein Kranenbarg, E., Hamdy, N.A.T., Putter, H., Heijns, J.B., van Warmerdam, L.J.C., Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., van Laarhoven, H.W.M., Vriens, B., Wasser, M.N., van Leeuwen-Stok, A.E., Liefers, G.J., van de Velde, C.J.H., Nortier, J.W.R., and Kroep, J.R.
- Published
- 2014
- Full Text
- View/download PDF
4. Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
- Author
-
de Groot, S., Janssen, L. G. M., Charehbili, A., Dijkgraaf, E. M., Smit, V. T. H. B. M., Kessels, L. W., van Bochove, A., van Laarhoven, H. W. M., Meershoek-Klein Kranenbarg, E., van Leeuwen-Stok, A. E., van de Velde, C. J. H., Putter, H., Nortier, J. W. R., van der Hoeven, J. J. M., Pijl, H., and Kroep, J. R.
- Published
- 2015
- Full Text
- View/download PDF
5. May I have your attention, please? : A neuroscientific study into message attention for health information
- Author
-
Kessels, L., Kok, Gerjo, Ruiter, Rob, van de Ven, Vincent, Work and Social Psychology, and RS: FPN WSP II
- Subjects
method ,information processing ,health information ,attention - Abstract
Realizing behaviour changes through health information is a difficult and complex task. This complexity is partly due to the way that people process health information. Aim of the research was to gain more insight into the underlying action mechanisms of various forms of health information, such as personally relevant and threatening health information. Attention processes for these two different messages were studied by measuring brain activity (EEG and fMRI), eye movements and reaction times during the processing of the information. The conclusion is that personally relevant health information can raise the attention, whereas presenting threatening health information can evoke defensive reactions.
- Published
- 2021
- Full Text
- View/download PDF
6. The Breast Size Satisfaction Survey (BSSS): Breast size dissatisfaction and its antecedents and outcomes in women from 40 nations
- Author
-
Swami, V., Tran, U.S., Barron, D., Afhami, R., Aimé, A., Almenara, C.A., Alp Dal, N., Amaral, A.C.S., Andrianto, S., Anjum, G., Argyrides, M., Atari, M., Aziz, M., Banai, B., Borowiec, J., Brewis, A., Cakir Kocak, Y., Campos, J.A.D.B., Carmona, C., Chaleeraktrakoon, T., Chen, H., Chobthamkit, P., Choompunuch, B., Constantinos, T., Crumlish, A., Cruz, J.E., Dalley, S.E., Damayanti, D., Dare, J., Donofrio, S.M., Draksler, A., Escasa-Dorne, M., Fernandez, E.F., Ferreira, M.E.C., Frederick, D.A., García, A.A., Geller, S., George, A., Ghazieh, L., Goian, C., Gorman, C., Grano, C., Handelzalts, J.E., Horsburgh, H., Jackson, T., Javela Delgado, L.G.J., Jović, Marija, Kantanista, A., Kertechian, S.K., Kessels, L., Król-Zielińska, M., Kuan, G., Kueh, Y.C., Kumar, S., Kvalem, I.L., Lombardo, C., Luis López Almada, E., Maïano, C., Manjary, M., Massar, K., Matera, C., Mereiles, J.F.F., Meskó, N., Namatame, Hikari, Nerini, A., Neto, F., Neto, J., Neves, A.N., Ng, S.-K., Nithiya, D.R., Omar, S.S., Omori, M., Panasiti, M.S., Pavela Banai, I., Pila, E., Pokrajac-Bulian, A., Postuvan, V., Prichard, I., Razmus, Magdalena, Sabiston, C.M., Sahlan, R.N., Sarfo, J.O., Sawamiya, Y., Stieger, S., SturtzSreetharan, C., Tee, E., ten Hoor, G.A., Thongpibul, K., Tipandjan, A., Tudorel, O., Tylka, Tracy L., Vally, Z., Vargas-Nieto, J.C., Vega, L.D., Vidal-Mollón, J., Vintila, M., Williams, D., Wutich, A., Yamamiya, Y., Zambrano, D., Zanetti, M.C., Živčić-Bećirević, I., Voracek, M., Swami, V., Tran, U.S., Barron, D., Afhami, R., Aimé, A., Almenara, C.A., Alp Dal, N., Amaral, A.C.S., Andrianto, S., Anjum, G., Argyrides, M., Atari, M., Aziz, M., Banai, B., Borowiec, J., Brewis, A., Cakir Kocak, Y., Campos, J.A.D.B., Carmona, C., Chaleeraktrakoon, T., Chen, H., Chobthamkit, P., Choompunuch, B., Constantinos, T., Crumlish, A., Cruz, J.E., Dalley, S.E., Damayanti, D., Dare, J., Donofrio, S.M., Draksler, A., Escasa-Dorne, M., Fernandez, E.F., Ferreira, M.E.C., Frederick, D.A., García, A.A., Geller, S., George, A., Ghazieh, L., Goian, C., Gorman, C., Grano, C., Handelzalts, J.E., Horsburgh, H., Jackson, T., Javela Delgado, L.G.J., Jović, Marija, Kantanista, A., Kertechian, S.K., Kessels, L., Król-Zielińska, M., Kuan, G., Kueh, Y.C., Kumar, S., Kvalem, I.L., Lombardo, C., Luis López Almada, E., Maïano, C., Manjary, M., Massar, K., Matera, C., Mereiles, J.F.F., Meskó, N., Namatame, Hikari, Nerini, A., Neto, F., Neto, J., Neves, A.N., Ng, S.-K., Nithiya, D.R., Omar, S.S., Omori, M., Panasiti, M.S., Pavela Banai, I., Pila, E., Pokrajac-Bulian, A., Postuvan, V., Prichard, I., Razmus, Magdalena, Sabiston, C.M., Sahlan, R.N., Sarfo, J.O., Sawamiya, Y., Stieger, S., SturtzSreetharan, C., Tee, E., ten Hoor, G.A., Thongpibul, K., Tipandjan, A., Tudorel, O., Tylka, Tracy L., Vally, Z., Vargas-Nieto, J.C., Vega, L.D., Vidal-Mollón, J., Vintila, M., Williams, D., Wutich, A., Yamamiya, Y., Zambrano, D., Zanetti, M.C., Živčić-Bećirević, I., and Voracek, M.
- Published
- 2020
7. EFFECTS OF GROWTH RETARDATION ON ACETYLCHOLINE-INDUCED ARTERIAL RELAXATION DEPEND ON THE TYPE OF PRENATAL INSULT.: 8.
- Author
-
Ruijtenbeek, K., Kessels, L., Blanco, C., and De Mey, J.
- Published
- 2001
8. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
- Author
-
Vergote, I. Scambia, G. O'Malley, D.M. Van Calster, B. Park, S.-Y. del Campo, J.M. Meier, W. Bamias, A. Colombo, N. Wenham, R.M. Covens, A. Marth, C. Raza Mirza, M. Kroep, J.R. Ma, H. Pickett, C.A. Monk, B.J. Park, S.Y. Song, Y.S. Makarova, Y. Trinidad, J. Ngan, H.Y.S. Aravantinos, G. Nam, J.-H. Gorbunova, V. Krikunova, L. Bae, D.-S. Arija, J.A.A. Mirza, M.R. Zamagni, C. Papandreou, C. Raspagliesi, F. Lisyanskaya, A. Benzaquen, A.O. Tognon, G. Ortega, E. Herraez, A.C. Buscema, J. Green, A. Burger, R. Sakaeva, D. Sanchez, A.R. Ghamande, S. King, L. Petru, E. Peen, U. Takeuchi, S. Ushijima, K. Martin, A.G. Kamelle, S. Carney, M. Forget, F. Bentley, J. Sehouli, J. Zola, P. Kato, H. Fadeeva, N. Gotovkin, E. Vladimirov, V. Marin, M.R. Alia, E.G. Shahin, M. Bhoola, S. Tewari, K. Anderson, D. Honhon, B. Pelgrims, J.G. Oza, A. Jimenez, J.G.-D. Hansen, V. Benjamin, I. Renard, V. Van den Bulck, H. Haenle, C. Koumakis, G. Yokota, H. Popov, V. Bradley, W. Wenham, R. Reid, R. McNamara, D. Friedman, R. Barlin, J. Spirtos, N. Chapman, J. Sevelda, P. Huizing, M. Lamot, C. Goffin, F. Hondt, L.D. Covens, A. Spadafora, S. Rautenberg, B. Reimer, T. Möbus, V. Hilpert, F. Gropp-Meier, M. Savarese, A. Pignata, S. Verderame, F. Mizuno, M. Takano, H. Ottevanger, P. Velasco, A.P. Palacio-Vazquez, I. Law, A. McIntyre, K. Teneriello, M. Fields, A. Lentz, S. Street, D. Schwartz, B. Mannel, R. Lim, P. Pulaski, H. Janni, W. Zorr, A. Karck, U. Cheng, A.C.K. Sorio, R. Gridelli, C. Aoki, D. Oishi, T. Hirashima, Y. Boere, I. Ferrer, E.F. Braly, P. Wilks, S. Lee, C. Schilder, J. Veljovich, D. Secord, A. Davis, K. Rojas-Espaillat, L. Lele, S. DePasquale, S. Squatrito, R. Schauer, C. Dirix, L. Vuylsteke, P. Joosens, E. Provencher, D. Lueck, H.-J. Hein, A. Burges, A. Canzler, U. Park-Simon, T.-W. Griesinger, F. Gadducci, A. Alabiso, O. Okamoto, A. Sawasaki, T. Saito, T. Ibañez, A.H. Calomeni, C. Spillman, M. Choksi, J. Taylor, N. Muller, C. Moore, D. DiSilvestro, P. Cunningham, M. Rose, P. Oppelt, P. Verhoeven, D. Graas, M.-P. Ghatage, P. Tonkin, K. Kurzeder, C. Schnappauf, B. Müller, V. Schmalzrie, H. Kalofonos, H. Bruzzone, M. Kroep, J. Diaz, C.C. Garcia, J.M. Polo, S.H. Garrison, M. Rocconi, R. Andrews, S. Bristow, R. McHale, M. Basil, J. Houck III, W. Bell, M. Cosin, J. Modesitt, S. Kendrick, J. Wade III, J. Wong, C. Evans, A. Buekers, T. Vanderkwaak, T. Ferriss, J. Darus, C. DAndre, S. Higgins, R. Monk, B. Bakkum-Gamez, J. DeMars, L. Van Le, L. Puls, L. Trehan, S. LaPolla, J. Michelson, E.D. Merchant, J. Peterson, C. Reid, G. Seago, D. Zweizig, S. Gajewski, W. Panwalkar, A. Leikermoser, R. Bogner, G. Debruyne, P. D'hondt, R. Berteloot, P. Kerger, J. Biagi, J. Castonguay, V. Welch, S. Muhic, A. Heubner, M. Grischke, E.-M. Rack, B. Fleisch, M. Lordick, F. Pectasides, D. Ho, W.M. Selvaggi, L. Vasquez, F.M. Villanueva, W.O.B. Alavez, A.M. Kessels, L. Bertran, A.S. Fernandez, C.M. Fabregat, M.B. Del Prete, S. Elkas, J. Cecchi, G. Kumar, P. Huh, W. Messing, M. Karimi, M. Kelley, A. Edraki, B. Mutch, D. Leiserowitz, G. Anderson, J. Lentz, S. Chambers, S. Morris, R. Waggoner, S. Gordon, A. Method, M. Johnson, P. Lord, R. Drake, J. Sivarajan, K. Midathada, M. Rice, K. Wadsworth, T. Pavelka, J. Edwards, R. Miller, D.S. Ford, P.L. Hurteau, J. Bender, D. Schimp, V. Creasman, W. Lerner, R. Chamberlain, D. Kueck, A. McDonald, J. Malad, S. Robinson-Bennett, B. Davidson, S. Krivak, T. Lestingi, T. Arango, H. Berard, P. Finkelstein, K. Gaur, R. Krasner, C. Ueland, F. Talmage, L. Yamada, S. Sutton, G. Potkul, R. Prasad-Hayes, M. Osborne, J. Celano, P. Thigpen, J. Sharma, S. Schilder, R. Tammela, J. Kemeny, M. Brown, A. Eisenhauer, E. Williams, J. Rowland, K. Nahum, K. Burke, J. Dar, Z. Fleming, N. Gibb, R. Guirguis, A. Herzog, T. John, V. Kumar, S. Kamat, A. Kassar, M. Leitao, M. Levine, L. Mendez, L. Patel, D. Berry, E. Warshal, D. Wolf, J. Zarwan, C. Collins, Y. Spitzer, G. Miller, B. Einstein, M. TRINOVA-3/ENGOT-ov2/GOG-3001 investigators
- Abstract
Background: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial. Methods: TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres)in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO)stage III to IV epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status of 0 or 1. Eligible patients were randomly assigned (2:1)using a permuted block method (block size of six patients)to receive six cycles of paclitaxel (175 mg/m2)and carboplatin (area under the serum concentration-time curve 5 or 6)every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. Maintenance therapy with trebananib or placebo continued for up to 18 additional months. The primary endpoint was progression-free survival, as assessed by the investigators, in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01493505, and is complete. Findings: Between Jan 30, 2012, and Feb 25, 2014, 1164 patients were screened and 1015 eligible patients were randomly allocated to treatment (678 to trebananib and 337 to placebo). After a median follow-up of 27·4 months (IQR 17·7–34·2), 626 patients had progression-free survival events (405 [60%]of 678 in the trebananib group and 221 [66%]of 337 in the placebo group). Median progression-free survival did not differ between the trebananib group (15·9 months [15·0–17·6])and the placebo group (15·0 months [12·6–16·1])groups (hazard ratio 0·93 [95% CI 0·79–1·09]; p=0·36). 512 (76%)of 675 patients in the trebananib group and 237 (71%)of 336 in the placebo group had grade 3 or worse treatment-emergent adverse events; of which the most common events were neutropenia (trebananib 238 [35%]vs placebo 126 [38%])anaemia (76 [11%]vs 40 [12%]), and leucopenia (81 [12%]vs 35 [10%]). 269 (40%)patients in the trebananib group and 104 (31%)in the placebo group had serious adverse events. Two fatal adverse events in the trebananib group were considered related to trebananib, paclitaxel, and carboplatin (lung infection and neutropenic colitis); two were considered to be related to paclitaxel and carboplatin (general physical health deterioration and platelet count decreased). No treatment-related fatal adverse events occurred in the placebo group. Interpretation: Trebananib plus carboplatin and paclitaxel did not improve progression-free survival as first-line treatment for advanced ovarian cancer. The combination of trebananib plus carboplatin and paclitaxel did not produce new safety signals. These results show that trebananib in combination with carboplatin and paclitaxel is minimally effective in this patient population. Funding: Amgen. © 2019 Elsevier Ltd
- Published
- 2019
9. We Lived in Medium.
- Author
-
Kessels, L. J.
- Subjects
INTERPERSONAL relations - Published
- 2022
10. De kwalificatie van vastgoedexploitatie in de inkomstenbelasting : wat is het onderscheid tussen de verschillende fiscale kwalificaties van vastgoed in de inkomstenbelasting en is dit een duidelijk onderscheid? : welke mogelijke oplossingen zijn er te vinden om de eventuele onduidelijkheid met betrekking tot dit onderscheid te beperken?
- Author
-
Kessels, L., Kessels, L., Kessels, L., and Kessels, L.
- Published
- 2016
11. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART
- Author
-
Hurley, C., AIDS Clinical Trials Group A5342 Protocol Team, Ritz, J., Storey, S., Gottesman, J., Sbrolla, A., Macatangay, B.J.C., Kessels, L., Arduino, R.C., Acosta, Ed., Perelson, A., Ray, G., Eron, J.J., Ledgerwood, J., Baer, J., Zheng, L., Lambert, N., Kudumu, M., Koup, R.A., Campbell, D., Tipton, M., Bunce, C.A., Epperson, K., Villamil, A.E., Sise, T., Casazza, J., Jennings, C., Dunaway, S., Tressler, R., Nair, A., Leonard, M., Cyktor, J.C., Bailer, R.T., Hite, M., Howard, J., Muttera, L., Clark, J., Weinman, R., Mellors, J.W., Durand, C.M., Koletar, S.L., Flynn, T., Benns, A., Keefer, M.C., Berzins, B., Currin, D., Riddler, S.A., Benson, C., Kittelson, P., Spitz, T., Wiggins, I., and Onesi, S.
- Abstract
Background. Broadly neutralizing monoclonal antibodies (bnMAbs) may promote clearance of HIV-1-expressing cells through antibody-dependent cell-mediated cytotoxicity. We evaluated the effect of the CD4-binding site bnMAb, VRC01, on measures of HIV-1 persistence in chronically infected individuals. Methods. A5342 was a phase 1, randomized, double-blind, placebo-controlled, parallel-arm study. Participants on effective antiretroviral therapy (ART) were randomized to receive 2 infusions of VRC01 (40 mg/kg) at entry and week 3, and 2 infusions of placebo (saline) at weeks 6 and 9; or 2 infusions of placebo at entry and week 3, and 2 infusions of VRC01 at weeks 6 and 9. Results. Infusion of VRC01 was safe and well tolerated. The median fold-change in the cell-associated HIV-1 RNA/DNA ratio from baseline to week 6 was 1.12 and 0.83 for the VRC01 and placebo arms, respectively, with no significant difference between arms (P = .16). There were no significant differences in the proportions with residual plasma viremia ≥1 copies/mL or in phorbol 12-myristate 13-acetate/ionomycin-induced virus production from CD4+ T cells between arms (both P > .05). Conclusions. In individuals with chronic HIV-1 infection on ART, VRC01 infusions were safe and well tolerated but did not affect plasma viremia, cellular HIV-1 RNA/DNA levels, or stimulated virus production from CD4+ T cells.
- Published
- 2018
- Full Text
- View/download PDF
12. The paradoxical effects of chronic intra-amniotic Ureaplasma exposure on ovine fetal brain development
- Author
-
Gussenhoven, R., Ophelders, D. R. M. G., Kemp, M., Payne, M. S., Spiller, Owen Bradley, Beeton, M.L., Stock, S., Cillero-Pastor, B., Barre, F. P. Y., Heeren, R. M. A., Kessels, L., Stevens, B., Rutten, B. P., Kallapur, S. G., Jobe, A. H., Kramer, B. W., and Wolfs, T. G. A. M.
- Abstract
Chorioamnionitis is associated with adverse neurodevelopmental outcomes in preterm infants. Ureaplasma spp. are the microorganisms most frequently isolated from the amniotic fluid of women diagnosed with chorioamnionitis. However, controversy remains concerning the role of Ureaplasma spp. in the pathogenesis of neonatal brain injury. We hypothesize that reexposure to an inflammatory trigger during the perinatal period might be responsible for the variation in brain outcomes of preterms following Ureaplasma-driven chorioamnionitis. To investigate these clinical scenarios, we performed a detailed multimodal study in which ovine neurodevelopmental outcomes were assessed following chronic intra-amniotic Ureaplasma parvum (UP) infection either alone or combined with subsequent lipopolysaccharide (LPS) exposure. We show that chronic intra-amniotic UP exposure during the second trimester provoked a decrease in astrocytes, increased oligodendrocyte numbers, and elevated 5-methylcytosine levels. In contrast, short-term LPS exposure before preterm birth induced increased microglial activation, myelin loss, elevation of 5-hydroxymethylcytosine levels, and lipid profile changes. These LPS-induced changes were prevented by chronic preexposure to UP (preconditioning). These data indicate that chronic UP exposure has dual effects on preterm brain development in utero. On the one hand, prolonged UP exposure causes detrimental cerebral changes that may predispose to adverse postnatal clinical outcomes. On the other, chronic intra-amniotic UP exposure preconditions the brain against a second inflammatory hit. This study demonstrates that microbial interactions and the timing and duration of the inflammatory insults determine the effects on the fetal brain. Therefore, this study helps to understand the complex and diverse postnatal neurological outcomes following UP driven chorioamnionitis.
- Published
- 2017
13. In hoeverre beperkt het nemo-tenetur beginsel, zoals dat voortvloeit uit artikel 6 EVRM, de informatieverplichting van artikel 47 AWR?
- Author
-
Kessels, L., Kessels, L., Kessels, L., and Kessels, L.
- Published
- 2014
14. May I have your attention, please? : A neuroscientific study into message attention for health information
- Author
-
Kessels, L., Kessels, L., Kessels, L., and Kessels, L.
- Abstract
Realizing behaviour changes through health information is a difficult and complex task. This complexity is partly due to the way that people process health information. Aim of the research was to gain more insight into the underlying action mechanisms of various forms of health information, such as personally relevant and threatening health information. Attention processes for these two different messages were studied by measuring brain activity (EEG and fMRI), eye movements and reaction times during the processing of the information. The conclusion is that personally relevant health information can raise the attention, whereas presenting threatening health information can evoke defensive reactions.
- Published
- 2010
15. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
- Author
-
Charehbili, A., Hamdy, N.A.T., Smit, V.T.H.B.M., Kessels, L., Bochove, A. van, Laarhoven, H.W. van, Putter, H., Kranenbarg, E.M.K., Leeuwen-Stok, A.E. van, Hoeven, J.J.M. van der, Velde, C.J.H. van de, Nortier, J.W.R., Kroep, J.R., Dutch Breast Canc Res Grp BOOG, Amsterdam Gastroenterology Endocrinology Metabolism, Cancer Center Amsterdam, and Oncology
- Subjects
0301 basic medicine ,Oncology ,Vitamin ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,25-Hydroxy-vitamin D ,Breast Neoplasms ,Neoadjuvant chemotherapy ,Biomarkers, Pharmacological ,Disease-Free Survival ,03 medical and health sciences ,chemistry.chemical_compound ,Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2] ,0302 clinical medicine ,Breast cancer ,Predictive Value of Tests ,Internal medicine ,Vitamin D and neurology ,Medicine ,Humans ,Neoadjuvant therapy ,Zoledronic acid ,Aged ,Calcifediol ,Neoplasm Staging ,Chemotherapy ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Neoadjuvant Therapy ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,030104 developmental biology ,Treatment Outcome ,chemistry ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Predictive value of tests ,Surgery ,Female ,Lymph Nodes ,business ,medicine.drug - Abstract
Item does not contain fulltext BACKGROUND: Serum levels of 25-OH vitamin D3 (vitamin D) have been shown to be prognostic for disease-free survival in patients with breast cancer. We investigated the predictive value of these levels for pathological response after neoadjuvant chemotherapy in patients with breast cancer taking part in the NEOZOTAC phase-III trial. Additionally, the effect of chemotherapy on vitamin D levels was studied. MATERIALS AND METHODS: Serum vitamin D was measured at baseline and before the last cycle of chemotherapy. The relationship between these measurements and clinical outcome, as defined by pathological complete response in breast and lymph nodes (pCR) was examined. RESULTS: Baseline and end of treatment vitamin D data were available in 169 and 91 patients, respectively. Median baseline vitamin D values were 58.0 nmol/L. In patients treated with chemotherapy only, serum vitamin D levels decreased during neoadjuvant chemotherapy (median decrease of 16 nmol/L, P = 0.003). The prevalence of vitamin D levels < 50 nmol/L increased from 38.3% at baseline to 55.9% after chemotherapy. In the total population, baseline and end of therapy vitamin D levels were not related to pathological response. No associations were found between pCR and vitamin D level changes. CONCLUSION: The significant decrease in vitamin D post-neoadjuvant chemotherapy suggests that vitamin D levels should be monitored and in case of decrease of vitamin D levels, correction may be beneficial for skeletal health and possibly breast cancer outcome.
- Published
- 2015
16. An analysis of the underlying corporate strategies for acquisitions
- Author
-
Kessels, L., Kessels, L., Kessels, L., and Kessels, L.
- Published
- 2005
17. PRENATAL EXPOSURE TO HYPEROXIA MODIFIES THE THROMBOXANE PRO STANOID RECEPTOR-MEDIATED RESPONSE TO H2O2 IN THE DUCTUS ARTERIOSUS OF THE CHICKEN EMBRYO
- Author
-
Van der Sterren, S., Kessels, L., Perez-Vizcaino, F., Cogolludo, A. L., Villamor, E., MUMC+: MA Arts Assistenten Kindergeneeskunde (9), RS: GROW - Developmental Biology, RS: GROW - R4 - Reproductive and Perinatal Medicine, and Kindergeneeskunde
- Subjects
ductus arteriosus ,normoxia ,hyperoxia ,hydrogen peroxide ,prostanoids ,thromboxane prostanoid receptor - Abstract
O-2 tension plays a critical role in the control of prenatal patency and postnatal closure of the ductus arteriosus (DA). We hypothesized that exposure of chicken embryos to hyperoxia alters the morphology and function of DA. Hyperoxia was induced by incubating fertilized eggs at 60% O-2 from day 15 to 19 of the 21-d incubation period. DA reactivity (assessed by wire myography), morphometry and mRNA expression of antioxidant enzymes were studied on day 19. Hyperoxic incubation neither affected embryonic growth nor induced signs of DA constriction or changed the mRNA expression of superoxide dismutase and catalase. The contractions induced by O-2(21%), KCl, 4-aminopyridine, phenylephrine, and endothelin-1 and the relaxations induced by acetylcholine (ACh), sodium nitroprusside, isoproterenol, and hydroxyfasudil were similar in DA from embryos incubated under normoxic or hyperoxic conditions. In contrast, hyperoxic incubation impaired the thromboxane prostanoid (TP) receptor-mediated contractions evoked by U46619, 15-E-2t,-Isoprostane and high concentrations (>= 3 mu M) of ACh. Exogenous hydrogen peroxide (H2O2) evoked endotheliumdependent contraction in the normoxic DA and endothelium-dependent relaxation in the hyperoxic group. The presence of the TP receptor antagonist SQ 29548 unmasked a relaxant response to H2O2 in the normoxic DA and the cyclooxygenase (COX) inhibitor indomethacin blocked H2O2-induced contraction (in the normoxic group) and relaxation (in the hyperoxic group). Altogether our functional data suggest that, in the chicken DA, exogenous H2O2 induces the release of endothelium-derived COX metabolite(s) with contractile and relaxant properties. Under normal conditions H2O2-induced contraction prevails and relaxation is unmasked after pharmacological or functional (i.e. hyperoxia) TP receptor impairment.
- Published
- 2014
18. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial
- Author
-
Boekhout, A.H., Gietema, J.A., Milojkovic Kerklaan, B., Werkhoven, E.D. van, Altena, R. van, Honkoop, A., Los, M., Smit, W.M., Nieboer, P., Smorenburg, C.H., Mandigers, C.M., Wouw, A.J. van de, Kessels, L, Velden, A.W. van der, Ottevanger, P.B., Smilde, T., Boer, J. den, Veldhuisen, D.J. van, Kema, I.P., Vries, E.G. de, Schellens, J.H., Boekhout, A.H., Gietema, J.A., Milojkovic Kerklaan, B., Werkhoven, E.D. van, Altena, R. van, Honkoop, A., Los, M., Smit, W.M., Nieboer, P., Smorenburg, C.H., Mandigers, C.M., Wouw, A.J. van de, Kessels, L, Velden, A.W. van der, Ottevanger, P.B., Smilde, T., Boer, J. den, Veldhuisen, D.J. van, Kema, I.P., Vries, E.G. de, and Schellens, J.H.
- Abstract
Item does not contain fulltext, IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether angiotensin II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects, defined as a decline in left ventricular ejection fraction (LVEF) of more than 15% or a decrease below the absolute value 45%. DESIGN: This randomized, placebo-controlled clinical study was conducted between October 2007 and October 2011 in 19 hospitals in the Netherlands, enrolling 210 women with early breast cancer testing positive for human epidermal growth factor receptor 2 (HER2) who were being considered for adjuvant systemic treatment with anthracycline-containing chemotherapy followed by trastuzumab. INTERVENTIONS: A total of 78 weeks of candesartan (32 mg/d) or placebo treatment; study treatment started at the same day as the first trastuzumab administration and continued until 26 weeks after completion of trastuzumab treatment. MAIN OUTCOMES AND MEASURES: The primary outcome was LVEF. Secondary end points included whether the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) can be used as surrogate markers and whether genetic variability in germline ERBB2 (formerly HER2 or HER2/neu) correlates with trastuzumab-related cardiotoxic effects. RESULTS: A total of 206 participants were evaluable (mean age, 49 years; age range, 25-69 years) 103 in the candesartan group (mean age, 50 years; age range, 25-69 years) and 103 in the placebo group (mean age, 50 years; age range, 30-67 years). Of these, 36 manifested at least 1 of the 2 primary cardiac end points. There were 3.8% more cardiac events in the candesartan group than in the placebo group (95% CI, -7% to 15%; P = .58): 20 events (19%) and 16 events (16%), respectively. The 2-year cumulative incidence of cardiac events wa
- Published
- 2016
19. The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists' group (BOOG) side-study
- Author
-
Dekker, T.J.A., Charehbili, A., Smit, V.T.H.B.M., Wasser, M.N.J.M., Heijns, J.B., Warmerdam, L.J. van, Kessels, L., Dercksen, W., Pepels, M., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Kranenbarg, E.M.K., Velde, C.J.H. van de, Liefers, G.J., Nortier, H.W.R., Tollenaar, R.A.E.M., Mesker, W.E., and Kroep, J.R.
- Published
- 2013
20. NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study
- Author
-
Charehbili, A., Ven, S. van de, Liefers, G.J., Smit, V.T.H.B.M., Putter, H., Heijns, J.B., Warmerdam, L. van, Kessels, L., Dercksen, W., Pepels, M.J., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Wasser, M.N., Hamdy, N.A.T., Kranenbarg, E.M.K., Leeuwen-Stok, E. van, Velde, C.J.H. van de, Kroep, J.R., and Nortier, J.W.R.
- Published
- 2013
21. A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study
- Author
-
Onstenk, W., Kraan, J., Charehbili, A., Mostert, B., Smit, V.T.H.B.M., Kroep, J.R., Nortier, J.W.R., Liefers, G.J., Ven, S. van de, Heijns, J.B., Kessels, L., Laarhoven, H.W.M. van, Bos, M.M.E.M., Velde, C.J.H. van de, Gratama, J.W., Sieuwerts, A.M., Martens, J.W.M., Foekens, J.A., and Sleijfer, S.
- Published
- 2013
22. Abstract P3-06-50: Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)
- Author
-
de Groot, S, primary, Charehbili, A, additional, Janssen, L GM, additional, Dijkgraaf, E M, additional, Smit, V THBM, additional, Kessels, L W, additional, van Bochove, A, additional, van Laarhoven, H WM, additional, Meershoek-Klein Kranenbarg, E, additional, van Leeuwen-Stok, A E, additional, Liefers, G J, additional, van de Velde, C JH, additional, Nortier, J WR, additional, van der Hoeven, J JM, additional, Pijl, H, additional, and Kroep, J R, additional
- Published
- 2015
- Full Text
- View/download PDF
23. Loss of DNAM-1 contributes to CD8+ T cell exhaustion in chronic HIV-1 infection
- Author
-
Cella, M, Presti, R, Vermi, William, Lavender, K, Turnbull, E, OCHSENBAUER JAMBOR, C, Kappes, Jc, Ferrari, G, Kessels, L, Williams, I, Mcmichael, Aj, Haynes, Bf, Borrow, P, and Colonna, M.
- Subjects
Antigens, Differentiation, T-Lymphocyte ,Programmed Cell Death 1 Receptor ,Down-Regulation ,HIV Infections ,T-Cell Antigen Receptor Specificity ,CD8-Positive T-Lymphocytes ,Lymphocytic Choriomeningitis ,Viral Load ,Lymphocyte Activation ,Virus Replication ,Article ,Peptide Fragments ,Mice ,Viral Proteins ,Antigens, CD ,HIV-1 ,Animals ,Humans ,Receptors, Virus ,Lymphocyte Count ,Apoptosis Regulatory Proteins ,Antigens, Viral ,Glycoproteins - Abstract
The hallmark of chronic viral infections is a progressive exhaustion of antigen-specific CD8(+) T cells that leads to persisting viral replication. It is generally believed that exhaustion is a consequence of the accumulation of multiple inhibitory receptors on CD8(+) T cells that makes them dysfunctional. Here, we show that during human chronic HIV-1 infection, a CD8(+) T-cell positive costimulatory pathway mediated by DNAX-activating molecule-1 is also disrupted. Thus, DNAX-activating molecule-1 downregulation on CD8(+) T cells aggravates the impairment of CTL effector function in chronic HIV-1 infection.
- Published
- 2010
24. A case-control pilot study on cognitive functioning, symptom validity and psychological wellbeing in HIV-1-infected patients in the Netherlands
- Author
-
Janssen, M.A.M., Bertens, D., Kessels, L., Kessels, R.P.C., Koopmans, P.P., Janssen, M.A.M., Bertens, D., Kessels, L., Kessels, R.P.C., and Koopmans, P.P.
- Abstract
Item does not contain fulltext, The objective of this study was to examine and relate both cognitive functioning and psychological wellbeing in Dutch HIV-1-infected patients (n = 30) in comparison with a matched healthy control group (n = 30), taking symptom validity into account. Significant differences in performance between patients and controls were found in the domain Working memory (P = 0.036), but not in the other cognitive domains. There was a significant difference in all dimensions of the psychological wellbeing scale, measured with the SCL-90-R (P values between 0.002 and 0.023), except for agoraphobia, cognitive performance difficulty and sleep disturbances. No correlations were found between the performance on the Working memory domain and wellbeing. Future research should focus on unravelling the underlying mechanisms of neurocognitive dysfunction further using neuropsychological tests, including a symptom validity test in combination with neuroimaging techniques in larger samples.
- Published
- 2013
25. Abstract P1-06-04: The predictive value of tumor-stroma ratio for radiological and pathological response to neoadjuvant chemotherapy in breast cancer (BC): A Dutch breast cancer trialists’ group (BOOG) side-study
- Author
-
Dekker, TJA, primary, Charehbili, A, additional, Smit, VTHBM, additional, Wasser, MNJM, additional, Heijns, JB, additional, van Warmerdam, LJ, additional, Kessels, L, additional, Dercksen, W, additional, Pepels, M, additional, Maartense, E, additional, van Laarhoven, HWM, additional, Vriens, B, additional, Meershoek-Klein Kranenbarg, E, additional, van de Velde, CJH, additional, Liefers, G-J, additional, Nortier, HWR, additional, Tollenaar, RAEM, additional, Mesker, WE, additional, and Kroep, JR, additional
- Published
- 2013
- Full Text
- View/download PDF
26. A case-control pilot study on cognitive functioning, symptom validity and psychological wellbeing in HIV-1-infected patients in the Netherlands
- Author
-
Janssen, M A M, primary, Bertens, D, additional, Kessels, L, additional, Kessels, R P C, additional, and Koopmans, P P, additional
- Published
- 2013
- Full Text
- View/download PDF
27. May I have your attention, please? : A neuroscientific study into message attention for health information
- Author
-
Kessels, L., primary
- Full Text
- View/download PDF
28. Effect Of Cyclosporine On Intraveneous Itraconazol Pharmacokinetics In Patients Receiving Allogenic Stem-cell Transplantation
- Author
-
Wilhelm, A J, primary, Kessels, L, additional, Timmers, G J, additional, van Loenen, A C, additional, and Huijgens, P C, additional
- Published
- 2005
- Full Text
- View/download PDF
29. Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
- Author
-
Groot, S., Janssen, L., Charehbili, A., Dijkgraaf, E., Smit, V., Kessels, L., Bochove, A., Laarhoven, H., Meershoek-Klein Kranenbarg, E., Leeuwen-Stok, A., Velde, C., Putter, H., Nortier, J., Hoeven, J., Pijl, H., and Kroep, J.
- Abstract
This side study investigated the effect of chemotherapy on thyroid function and the extent to which it can predict pathological complete response (pCR) in patients with early breast cancer taking part in NEOZOTAC phase III trial, randomizing between neoadjuvant chemotherapy with or without additional zoledronic acid. Moreover, we examined the impact of thyroid function on toxicity. Serum samples of 38 patients were available for analyses. Free thyroxin (fT4) and thyroid stimulating hormone (TSH) levels were compared between baseline and before the 6th cycle and between subjects with and without pCR. The relation between toxicity and the variation in fT4 and TSH levels during chemotherapy was tested. Samples at baseline and before the 6th cycle were available for 31 and 21 patients, respectively. The mean baseline fT4 level was 16.0 pmol/L and TSH level 1.11 mU/L, and these did not differ between both arms at each time point. During six cycles of chemotherapy, fT4 levels decreased ( p = 0.0001), and TSH levels increased significantly ( p = 0.019). Interestingly, the decrease of fT4 was significantly greater in patients without nausea, vomiting, or neuropathy, than in patients with those side effects ( p = 0.037, p = 0.043, and p = 0.050, respectively). Baseline TSH levels tended to be higher in patients with pCR ( p = 0.035 univariate analysis and p = 0.074 multivariate analysis). Chemotherapy blunts thyroid function, which was associated with less side effects. These data urge further evaluation of the effects of thyroid function on toxicity and outcome of breast cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
- Author
-
Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, and Tebas P
- Abstract
A significant proportion of human immunodeficiency virus (HIV) infected patients are coinfected with hepatitis B virus (HBV). Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance. Tenofovir disoproxil fumarate (TDF) is a nucleotide analog with excellent activity in vitro against HBV, which is also active against 3TC-resistant HBV variants. In this 24-week pilot study, the anti-HBV activity of TDF was prospectively evaluated in a cohort of 6 HIV coinfected subjects for whom 3TC and IFN therapy had previously failed. At baseline, all patients were taking 3TC or FTC and were hepatitis B surface antigen and hepatitis B e antigen positive; 4 had cirrhosis. Baseline HBV load was 7.95 log(10) copies/mL. By weeks 12 and 24, HBV load had decreased by 3.1 log(10) copies/mL and 4.3 log(10) copies/mL, respectively. There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals. Copyright © 2002 Infectious Diseases Society of America [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
31. Prenatal exposure to hyperoxiamodifies the thromboxane prostanoid receptor-mediated response to H2O2 in the ductus arteriosus of the chicken embryo
- Author
-
Sterren, S., Kessels, L., Perez-Vizcaino, F., Angel Cogolludo, and Villamor, E.
32. Effects of Chronic Hypoxia on The Sympathetic Innervation in Peripheral Arteries of The Chick Embryo.
- Author
-
Ruijtenbeek, K., Kessels, L., Janssen, G., Blanco, C., and De Mey, J.
- Published
- 1999
33. NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC).
- Author
-
van de Ven, S., Liefers, G-j, Putter, H., van Warmerdam, L. J., Kessels, L. W., Dercksen, W., Pepels, M. J., Maartense, E., van Laarhoven, H. W. M., Vriens, B., Smit, V. T. H. B. M., Wasser, M. N. J. M., Meershoek-Klein, Kranenbarg E. M., van Leeuwen-Stok, E., van de Velde, C. J. H, Nortier, J. W. R., and Kroep, J. R.
- Subjects
- *
DIPHOSPHONATES , *DRUG therapy , *CANCER treatment , *FEBRILE neutropenia , *TOXICITY testing - Abstract
Background: The role of bisphosphonates (BP) when added to the (neo)adjuvant treatment of BC in enhancing the efficacy of therapy is still unknown. NEOZOTAC investigates the efficacy of ZA added to neoadjuvant chemotherapy in patients with HER2-negative BC. Trial design: NEOZOTAC is a Dutch multicenter study. Patients are 1:1 randomized to 3-weekly TAC (docetaxel 75mg/m², adriamycin 50 mg/m² and cyclophosphamide 500 mg/m² i.v., day 1) chemotherapy supported by pegfilgrastim (6 mg sc), day 2 with or without ZA (4 mg i.v. within 24 hr after chemotherapy) q3 weeks. Eligibility criteria: Main inclusion criteria: stage II or III, measurable, HER2-negative BC, age ≥ 18 years, WHO 0-2, adequate bone marrow-, renal-, and liver function, absence of prior BP usage and absence of active dental problems. Study endpoint: The primary endpoint is the pathologic complete response (pCR) rate. Secondary endpoints are toxicity, clinical response, tumor heterogeneity in core biopsy vs. operation specimen, and (disease free) survival. Optional side studies include fluorescent imaging (SoftScan®), changes in bone markers, single nucleotide polymorphisms and the insulin-like growth factor pathway, circulating tumor and endothelial cells and the falsenegative rate of the sentinel node biopsy after neoadjuvant chemotherapy. Statistical Methods: Using a 5% significance level based on the two-sided Fishers exact test with a power of 80%, 250 patients (125/arm) are needed to show an improvement of the pCR-rate from 17% to 34% in the experimental arm. Randomization was done according to the Pococks minimisation technique stratified by cT, cN, and estrogen receptor status. Toxicity is analyzed using the Exact (2-sided) Chi-Square test. Results: From July 2010 to April 2012, 250 patients from 25 participating sites were randomized. Toxicity data of 173 patients are currently available and data of all 250 patients will be presented at SABCS. Patient characteristics are presented in table 1. Hematological and non-hematological toxicities were not significantly different between both treatment arms. Main grade 3/4 NCI-CTCv4 toxicities were neutropenia (8%), followed by febrile neutropenia (7%), fatigue (6%), diarrhea, hypertension, nausea (3%) and vomiting (1.2%). Bone pain, myalgia, and hypocalcemia occurred in one patient in the TAC-ZA arm (0.6%). Osteonecrosis of the jaw was not observed. Conclusions: Neoadjuvant TAC supported by pegfilgrastim plus ZA is feasible. No significant difference in toxicity are reported compared with the control arm. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. In vitro osteogenic and in ovo angiogenic effects of a family of natural origin P 2 O 5 -free bioactive glasses.
- Author
-
Nikody M, Kessels L, Morejón L, Schumacher M, Wolfs TGAM, Rademakers T, Delgado JA, Habibovic P, Moroni L, and Balmayor ER
- Abstract
Bioactive glasses (BGs) belong to a group of ceramic biomaterials having numerous applications due to their excellent biocompatibility and bioactivity. Depending on their composition, properties of BGs can be finely tuned. In this study, we investigated both angiogenic and osteogenic properties of a novel family of BGs from the SiO
2 -CaO-Na2 O system. Three BGs were synthesised from calcite minerals and silica sands extracted from natural deposits. Silica sands used for the synthesis of each glass were obtained from different depths of the deposit, resulting in a different colour and elemental composition. The composition and structural properties of the obtained BGs were determined. Direct culture of human mesenchymal stromal cells (hMSCs) with BG particles at different concentrations was used to investigate the biocompatibility as well as the osteogenic and angiogenic properties of the BGs. In addition, BGs' effect on angiogenesis was further studied in a chick chorioallantoic membrane (CAM) model. Material characterisation confirmed the amorphous character of BGs. Investigated BGs were biocompatible and stimulated early upregulation of RUNX2 , ALPL , COL1A1 , OCN , and OPN . All BGs tested in a CAM model positively influenced the number, distribution, and branching of the blood vessels. Furthermore, our study revealed that the depth of sand deposit, at which the raw material was collected, had an impact on the osteogenic and angiogenic properties of the resulting glasses. On the one hand, silica sand collected at the deepest layer of the deposit, featuring a higher content of Fe2 O3 and Al2 O3 , originated BGs with potent stimulative capacity of osteogenic and angiogenic gene expression. On the other hand, sand with high silica content and titanium ions resulted in a glass that better supported vessel structure. The BGs presented in this study showed the potential to promote osteogenesis and angiogenesis during bone tissue regeneration, and thus, they will be further studied as part of composite materials for the development of 3D implantable scaffolds., Competing Interests: There are no conflicts to declare., (This journal is © The Royal Society of Chemistry.)- Published
- 2024
- Full Text
- View/download PDF
35. Antenatal Ureaplasma Infection Causes Colonic Mucus Barrier Defects: Implications for Intestinal Pathologies.
- Author
-
van Gorp C, de Lange IH, Hütten MC, López-Iglesias C, Massy KRI, Kessels L, Knoops K, Cuijpers I, Sthijns MMJPE, Troost FJ, van Gemert WG, Spiller OB, Birchenough GMH, Zimmermann LJI, and Wolfs TGAM
- Subjects
- Pregnancy, Sheep, Animals, Humans, Female, Infant, Newborn, Intestines, Causality, Mucus, Chorioamnionitis, Ureaplasma Infections complications
- Abstract
Chorioamnionitis is a risk factor for necrotizing enterocolitis (NEC). Ureaplasma parvum (UP) is clinically the most isolated microorganism in chorioamnionitis, but its pathogenicity remains debated. Chorioamnionitis is associated with ileal barrier changes, but colonic barrier alterations, including those of the mucus barrier, remain under-investigated, despite their importance in NEC pathophysiology. Therefore, in this study, the hypothesis that antenatal UP exposure disturbs colonic mucus barrier integrity, thereby potentially contributing to NEC pathogenesis, was investigated. In an established ovine chorioamnionitis model, lambs were intra-amniotically exposed to UP or saline for 7 d from 122 to 129 d gestational age. Thereafter, colonic mucus layer thickness and functional integrity, underlying mechanisms, including endoplasmic reticulum (ER) stress and redox status, and cellular morphology by transmission electron microscopy were studied. The clinical significance of the experimental findings was verified by examining colon samples from NEC patients and controls. UP-exposed lambs have a thicker but dysfunctional colonic mucus layer in which bacteria-sized beads reach the intestinal epithelium, indicating undesired bacterial contact with the epithelium. This is paralleled by disturbed goblet cell MUC2 folding, pro-apoptotic ER stress and signs of mitochondrial dysfunction in the colonic epithelium. Importantly, the colonic epithelium from human NEC patients showed comparable mitochondrial aberrations, indicating that NEC-associated intestinal barrier injury already occurs during chorioamnionitis. This study underlines the pathogenic potential of UP during pregnancy; it demonstrates that antenatal UP infection leads to severe colonic mucus barrier deficits, providing a mechanistic link between antenatal infections and postnatal NEC development.
- Published
- 2024
- Full Text
- View/download PDF
36. Antenatal Ureaplasma infection induces ovine small intestinal goblet cell defects: a strong link with NEC pathology.
- Author
-
van Gorp C, de Lange IH, Hütten MC, López-Iglesias C, Massy KR, Kessels L, Kramer B, van de Wetering W, Spiller B, Birchenough GM, van Gemert WG, Zimmermann LJ, and Wolfs TG
- Subjects
- Humans, Pregnancy, Animals, Sheep, Female, Goblet Cells pathology, Intestinal Mucosa, Mucus, Chorioamnionitis pathology, Ureaplasma Infections complications, Ureaplasma Infections pathology
- Abstract
Disruption of the intestinal mucus barrier and intestinal epithelial endoplasmic reticulum (ER) stress contribute to necrotizing enterocolitis (NEC). Previously, we observed intestinal goblet cell loss and increased intestinal epithelial ER stress following chorioamnionitis. Here, we investigated how chorioamnionitis affects goblet cells by assessing their cellular characteristics. Importantly, goblet cell features are compared with those in clinical NEC biopsies. Mucus thickness was assessed as read-out of goblet cell function. Fetal lambs were intra-amniotically (IA) infected for 7d at 122 gestational age with Ureaplasma parvum serovar-3 , the main microorganism clinically associated with chorioamnionitis. After preterm delivery, mucus thickness, goblet cell numbers, gut inflammation, epithelial proliferation and apoptosis and intestinal epithelial ER stress were investigated in the terminal ileum. Next, goblet cell morphological alterations (TEM) were studied and compared to human NEC samples. Ileal mucus thickness and goblet cell numbers were elevated following IA UP exposure. Increased pro-apoptotic ER stress, detected by elevated CHOP-positive cell counts and disrupted organelle morphology of secretory cells in the intestinal epithelium, was observed in IA UP exposed animals. Importantly, comparable cellular morphological alterations were observed in the ileum from NEC patients. In conclusion, UP-driven chorioamnionitis leads to a thickened ileal mucus layer and mucus hypersecretion from goblet cells. Since this was associated with pro-apoptotic ER stress and organelle disruption, mucus barrier alterations seem to occur at the expense of goblet cell resilience and may therefore predispose to detrimental intestinal outcomes. The remarkable overlap of these in utero findings with observations in NEC patients underscores their clinical relevance.
- Published
- 2023
- Full Text
- View/download PDF
37. Hypoxia-Driven Changes in a Human Intestinal Organoid Model and the Protective Effects of Hydrolyzed Whey.
- Author
-
de Lange IH, van Gorp C, Massy KRI, Kessels L, Kloosterboer N, Bjørnshave A, Stampe Ostenfeld M, Damoiseaux JGMC, Derikx JPM, van Gemert WG, and Wolfs TGAM
- Subjects
- Humans, Whey Proteins chemistry, Hydrolysis, Peptides analysis, Inflammation, Organoids, Whey chemistry, Hypoxia
- Abstract
Many whey proteins, peptides and protein-derived amino acids have been suggested to improve gut health through their anti-oxidant, anti-microbial, barrier-protective and immune-modulating effects. Interestingly, although the degree of hydrolysis influences peptide composition and, thereby, biological function, this important aspect is often overlooked. In the current study, we aimed to investigate the effects of whey protein fractions with different degrees of enzymatic hydrolysis on the intestinal epithelium in health and disease with a novel 2D human intestinal organoid (HIO) monolayer model. In addition, we aimed to assess the anti-microbial activity and immune effects of the whey protein fractions. Human intestinal organoids were cultured from adult small intestines, and a model enabling apical administration of nutritional components during hypoxia-induced intestinal inflammation and normoxia (control) in crypt-like and villus-like HIO was established. Subsequently, the potential beneficial effects of whey protein isolate (WPI) and two whey protein hydrolysates with a 27.7% degree of hydrolysis (DH28) and a 50.9% degree of hydrolysis (DH51) were assessed. In addition, possible immune modulatory effects on human peripheral immune cells and anti-microbial activity on four microbial strains of the whey protein fractions were investigated. Exposure to DH28 prevented paracellular barrier loss of crypt-like HIO following hypoxia-induced intestinal inflammation with a concomitant decrease in hypoxia inducible factor 1 alpha (HIF1α) mRNA expression. WPI increased Treg numbers and Treg expression of cluster of differentiation 25 (CD25) and CD69 and reduced CD4+ T cell proliferation, whereas no anti-microbial effects were observed. The observed biological effects were differentially mediated by diverse whey protein fractions, indicating that (degree of) hydrolysis influences their biological effects. Moreover, these new insights may provide opportunities to improve immune tolerance and promote intestinal health.
- Published
- 2023
- Full Text
- View/download PDF
38. Electrospun Scaffolds Functionalized with a Hydrogen Sulfide Donor Stimulate Angiogenesis.
- Author
-
Yao T, van Nunen T, Rivero R, Powell C, Carrazzone R, Kessels L, Wieringa PA, Hafeez S, Wolfs TGAM, Moroni L, Matson JB, and Baker MB
- Subjects
- Animals, Chorioallantoic Membrane, Human Umbilical Vein Endothelial Cells metabolism, Humans, Neovascularization, Physiologic, Tissue Engineering, Tissue Scaffolds, Hydrogen Sulfide metabolism, Hydrogen Sulfide pharmacology
- Abstract
Tissue-engineered constructs are currently limited by the lack of vascularization necessary for the survival and integration of implanted tissues. Hydrogen sulfide (H
2 S), an endogenous signaling gas (gasotransmitter), has been recently reported as a promising alternative to growth factors to mediate and promote angiogenesis in low concentrations. Yet, sustained delivery of H2 S remains a challenge. Herein, we have developed angiogenic scaffolds by covalent attachment of an H2 S donor to a polycaprolactone (PCL) electrospun scaffold. These scaffolds were engineered to include azide functional groups (on 1, 5, or 10% of the PCL end groups) and were modified using a straightforward click reaction with an alkyne-functionalized N -thiocarboxyanhydride (alkynyl-NTA). This created H2 S-releasing scaffolds that rely on NTA ring-opening in water followed by conversion of released carbonyl sulfide into H2 S. These functionalized scaffolds showed dose-dependent release of H2 S based on the amount of NTA functionality within the scaffold. The NTA-functionalized fibrous scaffolds supported human umbilical vein endothelial cell (HUVEC) proliferation, formed more confluent endothelial monolayers, and facilitated the formation of tight cell-cell junctions to a greater extent than unfunctionalized scaffolds. Covalent conjugation of H2 S donors to scaffolds not only promotes HUVEC proliferation in vitro , but also increases neovascularization in ovo , as observed in the chick chorioallantoic membrane assay. NTA-functionalized scaffolds provide localized control over vascularization through the sustained delivery of a powerful endogenous angiogenic agent, which should be further explored to promote angiogenesis in tissue engineering.- Published
- 2022
- Full Text
- View/download PDF
39. Thiol-ene conjugation of VEGF peptide to electrospun scaffolds as potential application for angiogenesis.
- Author
-
Yao T, Chen H, Wang R, Rivero R, Wang F, Kessels L, Agten SM, Hackeng TM, Wolfs TGAM, Fan D, Baker MB, and Moroni L
- Abstract
Vascular endothelial growth factor (VEGF) plays a vital role in promoting attachment and proliferation of endothelial cells, and induces angiogenesis. In recent years, much research has been conducted on functionalization of tissue engineering scaffolds with VEGF or VEGF-mimetic peptide to promote angiogenesis. However, most chemical reactions are nonspecific and require organic solvents, which can compromise control over functionalization and alter peptide/protein activity. An attractive alternative is the fabrication of functionalizable electrospun fibers, which can overcome these hurdles. In this study, we used thiol-ene chemistry for the conjugation of a VEGF-mimetic peptide to the surface of poly (ε-caprolactone) (PCL) fibrous scaffolds with varying amounts of a functional PCL-diacrylate (PCL-DA) polymer. 30% PCL-DA was selected due to homogeneous fiber morphology. A VEGF-mimetic peptide was then immobilized on PCL-DA fibrous scaffolds by a light-initiated thiol-ene reaction. 7-Mercapto-4-methylcoumarin, RGD-FITC peptide and VEGF-TAMRA mimetic peptide were used to validate the thiol-ene reaction with fibrous scaffolds. Tensile strength and elastic modulus of 30% PCL-DA fibrous scaffolds were significantly increased after the reaction. Conjugation of 30% PCL-DA fibrous scaffolds with VEGF peptide increased the surface water wettability of the scaffolds. Patterned structures could be obtained after using a photomask on the fibrous film. Moreover, in vitro studies indicated that scaffolds functionalized with the VEGF-mimetic peptide were able to induce phosphorylation of VEGF receptor and enhanced HUVECs survival, proliferation and adhesion. A chick chorioallantoic membrane (CAM) assay further indicated that the VEGF peptide functionalized scaffolds are able to promote angiogenesis in vivo . These results show that scaffold functionalization can be controlled via a simple polymer mixing approach, and that the functionalized VEGF peptide-scaffolds have potential for vascular tissue regeneration., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
40. Intestinal Goblet Cell Loss during Chorioamnionitis in Fetal Lambs: Mechanistic Insights and Postnatal Implications.
- Author
-
van Gorp C, de Lange IH, Massy KRI, Kessels L, Jobe AH, Cleutjens JPM, Kemp MW, Saito M, Usada H, Newnham J, Hütten M, Kramer BW, Zimmermann LJ, and Wolfs TGAM
- Subjects
- Animals, Animals, Newborn, Apoptosis, Cell Count, Cell Differentiation, Chorioamnionitis chemically induced, Disease Models, Animal, Endoplasmic Reticulum Stress, Enterocolitis, Necrotizing chemically induced, Female, Gestational Age, Humans, Lipopolysaccharides adverse effects, Pregnancy, Premature Birth, Sheep, Chorioamnionitis pathology, Chorioamnionitis veterinary, Enterocolitis, Necrotizing pathology, Enterocolitis, Necrotizing rehabilitation, Enterocolitis, Necrotizing veterinary, Fetus pathology, Goblet Cells pathology
- Abstract
Chorioamnionitis, an important cause of preterm birth, is linked to necrotizing enterocolitis (NEC). NEC is characterized by a disrupted mucus barrier, goblet cell loss, and endoplasmic reticulum (ER) stress of the intestinal epithelium. These findings prompted us to investigate the mechanisms underlying goblet cell alterations over time in an ovine chorioamnionitis model. Fetal lambs were intra-amniotically (IA) exposed to lipopolysaccharides (LPS) for 5, 12, or 24 h, or 2, 4, 8, or 15 d before premature delivery at 125 d gestational age (GA). Gut inflammation, the number, distribution, and differentiation of goblet cells, ER stress, and apoptosis were measured. We found a biphasic reduction in goblet cell numbers 24 h-2 d after, and 15 d after IA LPS exposure. The second decrease of goblet cell numbers was preceded by intestinal inflammation, apoptosis, and crypt ER stress, and increased SAM-pointed domain-containing ETS transcription factor (SPDEF)-positive cell counts. Our combined findings indicated that ER stress drives apoptosis of maturating goblet cells during chorioamnionitis, ultimately reducing goblet cell numbers. As similar changes have been described in patients suffering from NEC, these findings are considered to be clinically important for understanding the predecessors of NEC, and targeting ER stress in this context is interesting for future therapeutics.
- Published
- 2021
- Full Text
- View/download PDF
41. The Breast Size Satisfaction Survey (BSSS): Breast size dissatisfaction and its antecedents and outcomes in women from 40 nations.
- Author
-
Swami V, Tran US, Barron D, Afhami R, Aimé A, Almenara CA, Alp Dal N, Amaral ACS, Andrianto S, Anjum G, Argyrides M, Atari M, Aziz M, Banai B, Borowiec J, Brewis A, Cakir Kocak Y, Campos JADB, Carmona C, Chaleeraktrakoon T, Chen H, Chobthamkit P, Choompunuch B, Constantinos T, Crumlish A, Cruz JE, Dalley SE, Damayanti D, Dare J, Donofrio SM, Draksler A, Escasa-Dorne M, Fernandez EF, Ferreira MEC, Frederick DA, García AA, Geller S, George A, Ghazieh L, Goian C, Gorman C, Grano C, Handelzalts JE, Horsburgh H, Jackson T, Javela Delgado LGJ, Jović M, Jović M, Kantanista A, Kertechian SK, Kessels L, Król-Zielińska M, Kuan G, Kueh YC, Kumar S, Kvalem IL, Lombardo C, Luis López Almada E, Maïano C, Manjary M, Massar K, Matera C, Mereiles JFF, Meskó N, Namatame H, Nerini A, Neto F, Neto J, Neves AN, Ng SK, Nithiya DR, Omar SS, Omori M, Panasiti MS, Pavela Banai I, Pila E, Pokrajac-Bulian A, Postuvan V, Prichard I, Razmus M, Sabiston CM, Sahlan RN, Sarfo JO, Sawamiya Y, Stieger S, SturtzSreetharan C, Tee E, Ten Hoor GA, Thongpibul K, Tipandjan A, Tudorel O, Tylka T, Vally Z, Vargas-Nieto JC, Vega LD, Vidal-Mollón J, Vintila M, Williams D, Wutich A, Yamamiya Y, Zambrano D, Zanetti MC, Živčić-Bećirević I, and Voracek M
- Subjects
- Adult, Female, Humans, Organ Size, Body Dissatisfaction psychology, Breast, Global Health, Personal Satisfaction
- Abstract
The Breast Size Satisfaction Survey (BSSS) was established to assess women's breast size dissatisfaction and breasted experiences from a cross-national perspective. A total of 18,541 women were recruited from 61 research sites across 40 nations and completed measures of current-ideal breast size discrepancy, as well as measures of theorised antecedents (personality, Western and local media exposure, and proxies of socioeconomic status) and outcomes (weight and appearance dissatisfaction, breast awareness, and psychological well-being). In the total dataset, 47.5 % of women wanted larger breasts than they currently had, 23.2 % wanted smaller breasts, and 29.3 % were satisfied with their current breast size. There were significant cross-national differences in mean ideal breast size and absolute breast size dissatisfaction, but effect sizes were small (η
2 = .02-.03). The results of multilevel modelling showed that greater Neuroticism, lower Conscientiousness, lower Western media exposure, greater local media exposure, lower financial security, and younger age were associated with greater breast size dissatisfaction across nations. In addition, greater absolute breast size dissatisfaction was associated with greater weight and appearance dissatisfaction, poorer breast awareness, and poorer psychological well-being across nations. These results indicate that breast size dissatisfaction is a global public health concern linked to women's psychological and physical well-being., (Copyright © 2020 Elsevier Ltd. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
42. Electrical stimulation promotes the angiogenic potential of adipose-derived stem cells.
- Author
-
Beugels J, Molin DGM, Ophelders DRMG, Rutten T, Kessels L, Kloosterboer N, Grzymala AAP, Kramer BWW, van der Hulst RRWJ, and Wolfs TGAM
- Subjects
- Adipocytes radiation effects, Animals, Apoptosis genetics, Apoptosis radiation effects, Cell Differentiation radiation effects, Cells, Cultured, Chick Embryo, Culture Media, Conditioned pharmacology, Electric Stimulation, Gene Expression Regulation, Developmental radiation effects, Humans, Mesenchymal Stem Cells radiation effects, Morphogenesis genetics, Neovascularization, Physiologic physiology, Stem Cells radiation effects, Transplants radiation effects, Mesenchymal Stem Cells cytology, Morphogenesis radiation effects, Neovascularization, Physiologic radiation effects, Transplants growth & development
- Abstract
Autologous fat transfer (AFT) is limited by post-operative volume loss due to ischemia-induced cell death in the fat graft. Previous studies have demonstrated that electrical stimulation (ES) promotes angiogenesis in a variety of tissues and cell types. In this study we investigated the effects of ES on the angiogenic potential of adipose-derived stem cells (ASC), important progenitor cells in fat grafts with proven angiogenic potential. Cultured human ASC were electrically stimulated for 72 hours after which the medium of stimulated (ES) and non-stimulated (control) ASC was analysed for angiogenesis-related proteins by protein array and ELISA. The functional effect of ES on angiogenesis was then assessed in vitro and in vivo. Nine angiogenesis-related proteins were detected in the medium of electrically (non-)stimulated ASC and were quantified by ELISA. The pro-angiogenic proteins VEGF and MCP-1 were significantly increased following ES compared to controls, while the anti-angiogenic factor Serpin E1/PAI-1 was significantly decreased. Despite increased levels of anti-angiogenic TSP-1 and TIMP-1, medium of ES-treated ASC significantly increased vessel density, total vessel network length and branching points in chorio-allantoic membrane assays. In conclusion, our proof-of-concept study showed that ES increased the angiogenic potential of ASC both in vitro and in vivo.
- Published
- 2019
- Full Text
- View/download PDF
43. Protection of the Ovine Fetal Gut against Ureaplasma -Induced Chorioamnionitis: A Potential Role for Plant Sterols.
- Author
-
van Gorp C, de Lange IH, Spiller OB, Dewez F, Cillero Pastor B, Heeren RMA, Kessels L, Kloosterboer N, van Gemert WG, Beeton ML, Stock SJ, Jobe AH, Payne MS, Kemp MW, Zimmermann LJ, Kramer BW, Plat J, and Wolfs TGAM
- Subjects
- Animals, Female, Pregnancy, Animal Feed analysis, Animal Nutritional Physiological Phenomena, Diet veterinary, Drug Administration Routes, Fetus, Inflammation drug therapy, Inflammation etiology, Inflammation veterinary, Random Allocation, Sheep, Chorioamnionitis microbiology, Chorioamnionitis prevention & control, Chorioamnionitis veterinary, Gastrointestinal Diseases microbiology, Gastrointestinal Diseases prevention & control, Gastrointestinal Diseases veterinary, Phytosterols administration & dosage, Phytosterols chemistry, Phytosterols pharmacology, Sheep Diseases microbiology, Sheep Diseases prevention & control, Ureaplasma, Ureaplasma Infections microbiology, Ureaplasma Infections prevention & control, Ureaplasma Infections veterinary
- Abstract
Chorioamnionitis, clinically most frequently associated with Ureaplasma , is linked to intestinal inflammation and subsequent gut injury. No treatment is available to prevent chorioamnionitis-driven adverse intestinal outcomes. Evidence is increasing that plant sterols possess immune-modulatory properties. Therefore, we investigated the potential therapeutic effects of plant sterols in lambs intra-amniotically (IA) exposed to Ureaplasma . Fetal lambs were IA exposed to Ureaplasma parvum ( U. parvum , UP) for six days from 127 d-133 d of gestational age (GA). The plant sterols β-sitosterol and campesterol, dissolved with β-cyclodextrin (carrier), were given IA every two days from 122 d-131 d GA. Fetal circulatory cytokine levels, gut inflammation, intestinal injury, enterocyte maturation, and mucosal phospholipid and bile acid profiles were measured at 133 d GA (term 150 d). IA plant sterol administration blocked a fetal inflammatory response syndrome. Plant sterols reduced intestinal accumulation of proinflammatory phospholipids and tended to prevent mucosal myeloperoxidase-positive (MPO) cell influx, indicating an inhibition of gut inflammation. IA administration of plant sterols and carrier diminished intestinal mucosal damage, stimulated maturation of the immature epithelium, and partially prevented U. parvum -driven reduction of mucosal bile acids. In conclusion, we show that β-sitosterol and campesterol administration protected the fetus against adverse gut outcomes following UP-driven chorioamnionitis by preventing intestinal and systemic inflammation.
- Published
- 2019
- Full Text
- View/download PDF
44. The Paradoxical Effects of Chronic Intra-Amniotic Ureaplasma parvum Exposure on Ovine Fetal Brain Development.
- Author
-
Gussenhoven R, Ophelders DRMG, Kemp MW, Payne MS, Spiller OB, Beeton ML, Stock SJ, Cillero-Pastor B, Barré FPY, Heeren RMA, Kessels L, Stevens B, Rutten BP, Kallapur SG, Jobe AH, Kramer BW, and Wolfs TGAM
- Subjects
- Amniotic Fluid drug effects, Animals, Brain drug effects, Female, Lipopolysaccharides pharmacology, Pregnancy, Sheep, Brain embryology, Chorioamnionitis pathology, Fetal Development drug effects, Ureaplasma, Ureaplasma Infections
- Abstract
Chorioamnionitis is associated with adverse neurodevelopmental outcomes in preterm infants. Ureaplasma spp. are the microorganisms most frequently isolated from the amniotic fluid of women diagnosed with chorioamnionitis. However, controversy remains concerning the role of Ureaplasma spp. in the pathogenesis of neonatal brain injury. We hypothesize that reexposure to an inflammatory trigger during the perinatal period might be responsible for the variation in brain outcomes of preterms following Ureaplasma-driven chorioamnionitis. To investigate these clinical scenarios, we performed a detailed multimodal study in which ovine neurodevelopmental outcomes were assessed following chronic intra-amniotic Ureaplasma parvum (UP) infection either alone or combined with subsequent lipopolysaccharide (LPS) exposure. We show that chronic intra-amniotic UP exposure during the second trimester provoked a decrease in astrocytes, increased oligodendrocyte numbers, and elevated 5-methylcytosine levels. In contrast, short-term LPS exposure before preterm birth induced increased microglial activation, myelin loss, elevation of 5-hydroxymethylcytosine levels, and lipid profile changes. These LPS-induced changes were prevented by chronic preexposure to UP (preconditioning). These data indicate that chronic UP exposure has dual effects on preterm brain development in utero. On the one hand, prolonged UP exposure causes detrimental cerebral changes that may predispose to adverse postnatal clinical outcomes. On the other, chronic intra-amniotic UP exposure preconditions the brain against a second inflammatory hit. This study demonstrates that microbial interactions and the timing and duration of the inflammatory insults determine the effects on the fetal brain. Therefore, this study helps to understand the complex and diverse postnatal neurological outcomes following UP driven chorioamnionitis., (The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2017
- Full Text
- View/download PDF
45. Hypoxia-induced contraction of chicken embryo mesenteric arteries: mechanisms and developmental changes.
- Author
-
Brinks L, Moonen RM, Moral-Sanz J, Barreira B, Kessels L, Perez-Vizcaino F, Cogolludo A, and Villamor E
- Subjects
- Animals, Chick Embryo, Embryonic Development, Muscle Contraction, Hypoxia physiopathology, Mesenteric Arteries embryology, Mesenteric Arteries physiopathology, Muscle, Smooth, Vascular embryology, Muscle, Smooth, Vascular physiopathology, Vasoconstriction
- Abstract
The fetal cardiovascular responses to acute hypoxia include a redistribution of the cardiac output toward the heart and the brain at the expense of other organs, such as the intestine. We hypothesized that hypoxia exerts a direct effect on the mesenteric artery (MA) that may contribute to this response. Using wire myography, we investigated the response to hypoxia (Po
2 ~2.5 kPa for 20 min) of isolated MAs from 15- to 21-day chicken embryos (E15, E19, E21), and 1- to 45-day-old chickens (P1, P3, P14, P45). Agonist-induced pretone or an intact endothelium were not required to obtain a consistent and reproducible response to hypoxia, which showed a pattern of initial rapid phasic contraction followed by a sustained tonic contraction. Phasic contraction was reduced by elimination of extracellular Ca2+ or by presence of the neurotoxin tetrodotoxin, the α1 -adrenoceptor antagonist prazosin, or inhibitors of L-type voltage-gated Ca2+ channels (nifedipine), mitochondrial electron transport chain (rotenone and antimycin A), and NADPH oxidase (VAS2870). The Rho-kinase inhibitor Y27632 impaired both phasic and tonic contraction and, when combined with elimination of extracellular Ca2+ , hypoxia-induced contraction was virtually abolished. Hypoxic MA contraction was absent at E15 but present from E19 and increased toward the first days posthatching. It then decreased during the first weeks of life and P45 MAs were unable to sustain hypoxia-induced contraction over time. In conclusion, the results of the present study demonstrate that hypoxic vasoconstriction is an intrinsic feature of chicken MA vascular smooth muscle cells during late embryogenesis and the perinatal period., (Copyright © 2016 the American Physiological Society.)- Published
- 2016
- Full Text
- View/download PDF
46. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
- Author
-
Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, and Schellens JH
- Subjects
- Adult, Aged, Angiotensin Receptor Antagonists therapeutic use, Biphenyl Compounds, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cardiotoxicity blood, Cardiotoxicity diagnostic imaging, Cardiotoxicity etiology, Chemotherapy, Adjuvant, Double-Blind Method, Echocardiography, Female, Genetic Variation, Genotype, Humans, Middle Aged, Multivariate Analysis, Natriuretic Peptide, Brain blood, Neoplasm Staging, Netherlands, Odds Ratio, Peptide Fragments blood, Polymorphism, Single Nucleotide, Receptor, ErbB-2 metabolism, Stroke Volume, Troponin T blood, Ventricular Function, Left, Angiotensin II Type 1 Receptor Blockers therapeutic use, Antineoplastic Agents adverse effects, Benzimidazoles therapeutic use, Breast Neoplasms drug therapy, Cardiotoxicity prevention & control, Receptor, ErbB-2 genetics, Tetrazoles therapeutic use, Trastuzumab adverse effects
- Abstract
Importance: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects., Objective: To determine as the primary end point whether angiotensin II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects, defined as a decline in left ventricular ejection fraction (LVEF) of more than 15% or a decrease below the absolute value 45%., Design: This randomized, placebo-controlled clinical study was conducted between October 2007 and October 2011 in 19 hospitals in the Netherlands, enrolling 210 women with early breast cancer testing positive for human epidermal growth factor receptor 2 (HER2) who were being considered for adjuvant systemic treatment with anthracycline-containing chemotherapy followed by trastuzumab., Interventions: A total of 78 weeks of candesartan (32 mg/d) or placebo treatment; study treatment started at the same day as the first trastuzumab administration and continued until 26 weeks after completion of trastuzumab treatment., Main Outcomes and Measures: The primary outcome was LVEF. Secondary end points included whether the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) can be used as surrogate markers and whether genetic variability in germline ERBB2 (formerly HER2 or HER2/neu) correlates with trastuzumab-related cardiotoxic effects., Results: A total of 206 participants were evaluable (mean age, 49 years; age range, 25-69 years) 103 in the candesartan group (mean age, 50 years; age range, 25-69 years) and 103 in the placebo group (mean age, 50 years; age range, 30-67 years). Of these, 36 manifested at least 1 of the 2 primary cardiac end points. There were 3.8% more cardiac events in the candesartan group than in the placebo group (95% CI, -7% to 15%; P = .58): 20 events (19%) and 16 events (16%), respectively. The 2-year cumulative incidence of cardiac events was 0.28 (95% CI, 0.13-0.40) in the candesartan group and 0.16 (95% CI, 0.08-0.22) in the placebo group (P = .56). Candesartan did not affect changes in NT-proBNP and hs-TnT values, and these biomarkers were not associated with significant changes in LVEF. The Ala1170Pro homozygous ERBB2 genotype was associated with a lower likelihood of the occurrence of a cardiac event compared with Pro/Pro + Ala/Pro genotypes in multivariate analysis (odds ratio, 0.09; 95% CI, 0.02-0.45; P = .003)., Conclusions and Relevance: The findings do not support the hypothesis that concomitant use of candesartan protects against a decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer. The ERBB2 germline Ala1170Pro single nucleotide polymorphism may be used to identify patients who are at increased risk of trastuzumab-related cardiotoxic effects., Trial Registration: clinicaltrials.gov Identifier: NCT00459771.
- Published
- 2016
- Full Text
- View/download PDF
47. Prenatal exposure to hyperoxia modifies the thromboxane prostanoid receptor-mediated response to H2O2 in the ductus arteriosus of the chicken embryo.
- Author
-
van der Sterren S, Kessels L, Perez-Vizcaino F, Cogolludo AL, and Villamor E
- Subjects
- Animals, Bridged Bicyclo Compounds, Heterocyclic, Chick Embryo, Cyclooxygenase Inhibitors pharmacology, Ductus Arteriosus pathology, Fatty Acids, Unsaturated, Hydrazines pharmacology, Hydrogen Peroxide pharmacology, Hyperoxia pathology, Indomethacin pharmacology, Receptors, Thromboxane antagonists & inhibitors, Vasoconstriction drug effects, Vasodilation drug effects, Ductus Arteriosus physiology, Hyperoxia physiopathology, Receptors, Thromboxane physiology
- Abstract
O2 tension plays a critical role in the control of prenatal patency and postnatal closure of the ductus arteriosus (DA). We hypothesized that exposure of chicken embryos to hyperoxia alters the morphology and function of DA. Hyperoxia was induced by incubating fertilized eggs at 60% O2 from day 15 to 19 of the 21-d incubation period. DA reactivity (assessed by wire myography), morphometry and mRNA expression of antioxidant enzymes were studied on day 19. Hyperoxic incubation neither affected embryonic growth nor induced signs of DA constriction or changed the mRNA expression of superoxide dismutase and catalase. The contractions induced by O2 (21%), KCl, 4-aminopyridine, phenylephrine, and endothelin-1 and the relaxations induced by acetylcholine (ACh), sodium nitroprusside, isoproterenol, and hydroxyfasudil were similar in DA from embryos incubated under normoxic or hyperoxic conditions. In contrast, hyperoxic incubation impaired the thromboxane prostanoid (TP) receptor-mediated contractions evoked by U46619, 15-E2t-Isoprostane and high concentrations (≥3 μM) of ACh. Exogenous hydrogen peroxide (H2O2) evoked endothelium-dependent contraction in the normoxic DA and endothelium-dependent relaxation in the hyperoxic group. The presence of the TP receptor antagonist SQ 29548 unmasked a relaxant response to H2O2 in the normoxic DA and the cyclooxygenase (COX) inhibitor indomethacin blocked H2O2-induced contraction (in the normoxic group) and relaxation (in the hyperoxic group). Altogether our functional data suggest that, in the chicken DA, exogenous H2O2 induces the release of endothelium-derived COX metabolite(s) with contractile and relaxant properties. Under normal conditions H2O2-induced contraction prevails and relaxation is unmasked after pharmacological or functional (i.e.hyperoxia) TP receptor impairment.
- Published
- 2014
48. Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection.
- Author
-
Cella M, Presti R, Vermi W, Lavender K, Turnbull E, Ochsenbauer-Jambor C, Kappes JC, Ferrari G, Kessels L, Williams I, McMichael AJ, Haynes BF, Borrow P, and Colonna M
- Subjects
- Animals, Antigens, CD physiology, Antigens, Differentiation, T-Lymphocyte biosynthesis, Antigens, Differentiation, T-Lymphocyte genetics, Antigens, Viral immunology, Apoptosis Regulatory Proteins physiology, CD8-Positive T-Lymphocytes immunology, Down-Regulation, Glycoproteins immunology, HIV Infections virology, HIV-1 immunology, Humans, Lymphocyte Activation, Lymphocyte Count, Lymphocytic Choriomeningitis immunology, Mice, Peptide Fragments immunology, Programmed Cell Death 1 Receptor, Receptors, Virus immunology, T-Cell Antigen Receptor Specificity, Viral Load, Viral Proteins immunology, Virus Replication, T Lineage-Specific Activation Antigen 1, Antigens, Differentiation, T-Lymphocyte immunology, CD8-Positive T-Lymphocytes pathology, HIV Infections immunology, HIV-1 physiology
- Abstract
The hallmark of chronic viral infections is a progressive exhaustion of antigen-specific CD8(+) T cells that leads to persisting viral replication. It is generally believed that exhaustion is a consequence of the accumulation of multiple inhibitory receptors on CD8(+) T cells that makes them dysfunctional. Here, we show that during human chronic HIV-1 infection, a CD8(+) T-cell positive costimulatory pathway mediated by DNAX-activating molecule-1 is also disrupted. Thus, DNAX-activating molecule-1 downregulation on CD8(+) T cells aggravates the impairment of CTL effector function in chronic HIV-1 infection.
- Published
- 2010
- Full Text
- View/download PDF
49. Morphological and functional alterations of the ductus arteriosus in a chicken model of hypoxia-induced fetal growth retardation.
- Author
-
Van der Sterren S, Agren P, Zoer B, Kessels L, Blanco CE, and Villamor E
- Subjects
- Adrenergic Agonists pharmacology, Animals, Chickens, Ductus Arteriosus drug effects, Fetal Growth Retardation etiology, Regression Analysis, Vasodilator Agents pharmacology, Ductus Arteriosus metabolism, Ductus Arteriosus pathology, Fetal Growth Retardation pathology, Hypoxia complications
- Abstract
The hypoxic conditions in which children with intrauterine growth retardation (IUGR) develop are hypothesized to alter the development of the ductus arteriosus (DA). We aimed to evaluate the effects of in ovo hypoxia on chicken DA morphometry and reactivity. Hypoxia (15% O2 from day 6 to 19 of the 21-d incubation period) produced a reduction in the body mass of the 19-d fetuses and a shortening of right and left DAs. However, ductal lumen and media cross-sectional areas were not affected by hypoxia. The ductal contractions induced by oxygen, KCl, H2O2, 4-aminopyridine, and endothelin-1 were similar in control and hypoxic fetuses. In contrast, the DAs from the hypoxic fetuses showed increased contractile responses to norepinephrine and phenylephrine and impaired relaxations to acetylcholine, sodium nitroprusside, and isoproterenol. The relaxations induced by 8-Br-cGMP, forskolin, Y-27632, and hydroxyfasudil were not altered by chronic hypoxia. In conclusion, chronic in ovo hypoxia-induced growth retardation in fetal chickens and altered the response of the DA to adrenergic agonists and to endothelium-dependent and -independent relaxing agents. Our observations support the concept that prolonged patency of the DA in infants with IUGR may be partially related with hypoxia-induced changes in local vascular mechanisms.
- Published
- 2009
- Full Text
- View/download PDF
50. Effects of prenatal hypoxia on pulmonary vascular reactivity in chickens prone to pulmonary hypertension.
- Author
-
Zoer B, Kessels L, Vereijken A, De Mey JG, Bruggeman V, Decuypere E, Blanco CE, and Villamor E
- Subjects
- Acetylcholine pharmacology, Animals, Chick Embryo, Chickens, Disease Models, Animal, Endothelium, Vascular drug effects, Female, Hypertension, Pulmonary physiopathology, Nitroprusside pharmacology, Pulmonary Artery drug effects, Vasoconstriction, Vasodilation drug effects, Endothelium, Vascular metabolism, Hypertension, Pulmonary etiology, Hypoxia, Pulmonary Artery metabolism
- Abstract
Among chickens, meat-producing broiler strains are highly prone to develop severe pulmonary hypertension (PH) that is accompanied by endothelial dysfunction in the conduit extrapulmonary arteries. We hypothesized that exposure to chronic prenatal mild hypoxia would accelerate PH and endothelial dysfunction in smaller intrapulmonary arteries from broiler chickens. Fertilized broiler and layer (White Leghorn, WL) eggs were incubated under normoxic or hypoxic conditions. Endothelium-dependent (tested with acetylcholine, ACh ) and -independent (tested with sodium nitroprusside, SNP) relaxations of the caudomedial intrapulmonary artery were studied on fetal day 19 and at 2 weeks post-hatch. The response to acute hypoxia in vitro was also studied in the 2 wk-old vessels. Relaxations induced by ACh and SNP were similar in broiler and layer chickens and were unaffected by chronic mild hypoxia during incubation. However, during in vitro acute hypoxia the broiler arteries showed a markedly enhanced contraction. Chronic prenatal hypoxia did not affect the response of intrapulmonary arteries to acute hypoxia. We conclude that early endothelial dysfunction is not present in the small pulmonary arteries of fast-growing broilers after incubation under normoxic or hypoxic conditions. The higher susceptibility of the broiler pulmonary arteries to acute hypoxia might, at least partially, explain the higher susceptibility to PH.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.